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Ovariectomized (OVX) ratsBisphosphonates are widely used in the treatment of osteoporosis and contribute to the reduction of bone frac-
tures. Ibandronate (IBN) is a highly potent, nitrogen-containing bisphosphonate, which is administered orally or
intravenously at extended dosing intervals. Vitamin D or active vitamin D3 derivatives are also used in the treat-
ment of osteoporosis, and are oftenused in combinationwith other drugs. In this study,we investigated the effect
of treatment with the combination of once-monthly s.c. dosing of IBN plus once-daily oral eldecalcitol (ELD), an
active vitaminD3 derivative, using agedovariectomized (OVX) rats. Treatmentwas started theday afterOVX, and
analyses were performed 4, 8, and 12weeks thereafter by determination of bonemarkers, bonemineral density,
biomechanical properties, and histomorphometry. The combination treatment showed a synergistic effect in in-
creasing both lumbar and femoral BMD, and resulted in a signiﬁcant increase in bone ultimate load. The combi-
nation of IBN plus ELD acted synergistically to reduce bone resorption, whereas bone formation did not decrease
anymore thanwithmonotherapywith either IBNor ELD. Bone formation independent of bone resorption (a pro-
cess known as ‘minimodeling’) was not changed in vehicle treated OVX rats despite the increase in bone turn-
over. ELD upregulated minimodeling, which was however not diminished in the combination treatment. In
conclusion, treatment with the combination of IBN plus ELD was beneﬁcial in the treatment of osteoporosis in
aged OVX rats. It exhibited a synergistic inhibitory effect on bone resorption and keeps bone formation at the
level of sham controls. This uncoupling of bone resorption/bone formation was affected, to some extent, by
minimodeling-based bone formation which is independent of bone resorption. This combination regimen
which showed synergistic effect on BMD and bone ultimate load without inhibition of bone formation may be
beneﬁcial in long-term osteoporosis treatment to prevent bone fractures.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).; OVX, ovariectomized; MCT,
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Ibandronate (IBN) is a highly potent inhibitor of bone resorption
which was selected from among 300 bisphosphonate molecules [1].
IBN inhibits farnesyl diphosphate synthase (an enzyme correlated
with efﬁcacy of bone resorption) in osteoclasts more efﬁciently than
alendronate, another widely used bisphosphonate [2]. IBN can be ad-
ministered at extended between-dose intervals both intravenously
and orally, and is widely used in the treatment of osteoporosis [3–5].
IBN exhibits its anti-osteoporotic effect in a dose-dependent manner
[6], and the efﬁcacy of treatment is related to the total dose of IBN, inde-
pendent of the treatment regimen [7].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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treatment of osteoporosis in Japan [8]. Active vitamin D3 derivatives
such as ELD are frequently used in osteoporosis treatment in combina-
tion with other anti-osteoporotic drugs, not only because of their effect
in correcting the uptake of calcium from the intestine but also because
of their effect in reducing the incidence of bone fractures. However,
even under appropriate treatment, many patients with osteoporosis
nevertheless experience bone fractures, necessitating the establishment
of a more effective regimen.
In this study, we investigated the effect of a combination treatment
with IBN plus ELD on BMD, bone ultimate load, and bone turnover
using aged ovariectomized (OVX) rats. We also attempted to explain a
phenomenon of the uncoupling of bone formation/bone resorption
that was observed in the combination treatment by focusing on
minimodeling, which is deﬁned as bone formation independent of
bone resorption [9,10].2. Materials and methods
2.1. Animal experiments
Female Wistar–Imamichi rats were purchased from the Institute for
Animal Reproduction (Ibaraki, Japan) and sham-operated or ovariecto-
mized (OVX) when 8 months old to make a model for the study of es-
trogen deﬁciency. The experimental protocol was approved by the
Institutional Animal Care and Use Committee of Chugai Pharmaceutical
Co., Ltd. Animals were allowed free access to feed (CE-2; CLEA Japan,
Tokyo, Japan) in stainless steel feeders. Drinking water was provided
to the animals ad libitum via an automatic watering system. Glass
water bottles ﬁttedwith sipper tubeswere used during urine collection.2.1.1. A dose-ﬁnding experiment
From the day after surgery, OVX rats were treated with IBN (subcu-
taneously, once every 4 weeks, 3 times in total; 1, 3, 10, and 30 μg/kg)
for 12weeks. Isotonic sodium chloride solution (Otsuka Pharmaceutical
Factory, Tokushima, Japan) was used as the vehicle. At 12 weeks after
treatment, 24-h urine and serum from jugular vein bloodwere collected.
Lumbar vertebrae and femurs were collected at the end of the
experiment.2.1.2. A combined therapy experiment
From the day after surgery, OVX rats were treated with either IBN
(subcutaneously, once every 4 weeks, 3 times in total; 3 μg/kg), ELD
(orally, once daily, 15 ng/kg), or their combination for 12weeks. Isoton-
ic sodium chloride solution was used as the vehicle for IBN and
medium-chain triglyceride (MCT) (The Nisshin OilliO Group, Tokyo,
Japan) was used as the vehicle for ELD. Every 4 weeks, 24-h urine and
serum from jugular vein blood were collected. Seven days prior to
necropsy, 20 mg/kg tetracycline (Sigma-Aldrich, MO, USA) was subcu-
taneously administered; 2 days prior to necropsy, 10 mg/kg calcein
(Dojindo Laboratories, Kumamoto, Japan)was subcutaneously adminis-
tered. Lumbar vertebrae and femurs were collected at the end of the
experiment.2.2. Serum and urine analysis
Calcium and phosphorus in serum and creatinine (Cr) in urine were
measured using an automatic analyzer (Clinical Analyzer Model 7180;
HitachiHigh-Technologies Corporation, Tokyo, Japan). Serumosteocalcin
(OCN) and urine deoxypyridinoline (DPD) were measured by ELISA
(OCN: GE Healthcare Japan, Tokyo, Japan; DPD: DS Pharma Biomedical,
Osaka, Japan). The concentration of urinary DPD was normalized to the
concentration of urinary creatinine (Cr).2.3. Bone mineral density measurement
Bone mineral density (BMD) of the second to fourth lumbar verte-
brae (L2–L4) and right femurwas determined by dual-energy X-ray ab-
sorptiometry (DCS-600EX-IIIR; Hitachi Aloka Medical, Tokyo, Japan).
After dual-energy X-ray images were obtained, the long axis of the
femur was divided into 10 parts numbered F1 to F10 from the proximal
to distal ends, then BMD of thewhole (F1–F10), proximal (F1–F3), mid-
dle (F4–F7), and distal (F8–F10) femur was calculated.
2.4. Bone mechanical property measurement
To assess the bone mechanical properties of trabecular and cortical
bone, a compression test [11] for the L5 lumbar vertebra and a 3-point
bending test [12] for the middle femur were performed. The vertebral
arch and disk were removed from each L5 lumbar vertebra and
vertebral bodies were trimmed to a length of 5 mm on the vertical
axis. The trimmed vertebral bodieswere placed in a bone strength tester
(TK-252C; Muromachi Kikai, Tokyo, Japan), and compressive strength
wasmeasured by pressure at a speed of 2.5mm/min. The 3-point bend-
ing test of the femurwas performed by the same tester. Themidpoint of
the left femur was placed on a holding device, and the supports were
located 12 mm apart. The bending force was calculated at a speed of
20 mm/min until fractures occurred. From the load–displacement
curve, the ultimate load (N), stiffness (N/mm), and energy (mJ) were
obtained.
2.5. Bone histomorphometry analysis
Bone histomorphometry analysis was performed as previously
reported [13]. Brieﬂy, the third lumbar vertebral body (L3) and right
femur were ﬁxed in 70% ethanol and stained according to the method
of Villanueva [14]. After dehydration with ethanol and acetone, the
samples were embedded in methyl methacrylate (Wako Pure Chemical
Industries, Osaka, Japan).Midsagittal sections of L3, 5 μmthick, were ob-
tained with a microtome (Supercut 2050; Reichert-Jung, Heidelberg,
Germany). The cancellous bone within 1.7 mm from the growth plates
was excluded from the measurements. The image obtained under a
ﬂuorescence microscope was recorded with a digital camera and
the primary histomorphometric parameters were measured with an
image analyzing system (Cosmozone 1SA; Nikon, Tokyo, Japan). No-
menclature, symbols, and units used in this study are those described
in the Report of the American Society for Bone and Mineral Research
Nomenclature Committee [15]. New formed bones on smooth cement
lines were deﬁned as minimodeling.
2.6. Statistical analysis
All data are presented as means ± standard deviation (SD). Statisti-
cal analysis was performed by analysis of variance (ANOVA) on the SAS
statistical analysis software package (SAS institute Inc., Cary, NC, USA).
Statistical differences between Sham and Vehicle groups were analyzed
by unpaired t-test. In the dose-ﬁnding test, analysis of the sham group
vs. other groups was performed by Dunnett's multiple comparison
test. In the combination treatment test, analyses between the Vehicle
group and all other groups were analyzed by Tukey's multiple compar-
ison test. A value of p b 0.05 was considered signiﬁcant for all statistical
analyses.
3. Results
3.1. A dose-ﬁnding experiment
Prior to researching the IBN plus ELD combination treatment, we
performed the dose-ﬁnding experiment of IBN in OVX rats. Urinary
DPD, a bone resorption marker, and serum OCN, a bone formation
Fig. 1.Ratswere ovariectomized and administered the indicateddose of IBN from the day after surgery. Urine and serumwere collected after 12week's treatment. (A) OVX increased bone
turnover markers, and IBN reduced both bone resorption and bone formation. Urinary DPD and serum OCN were calculated by ELISA. (B) IBN increased lumbar BMD (L2–L4) and total
femoral BMD.Mean±SD. n=7. *, p b 0.05 vs. shambyDunnett'smultiple comparison test. IBN, ibandronate; DPD, deoxypiridinorine; Cr, creatinine; OCN, osteocalcin; BMD, bonemineral
density.
Table 1
Combination treatment study design.
Group n Surgery Treatment Dose
Sham 10 Sham Vehicle –
Vehicle 10 OVX Vehicle –
IBN 10 OVX IBN 3 μg/kg/4 weeks
ELD 10 OVX ELD 15 ng/kg/day
Combination 10 OVX IBN 3 μg/kg/4 weeks
ELD 15 ng/kg/day
IBN, ibandronate; ELD, eldecalcitol; OVX, ovariectomized.
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IBN showed a signiﬁcant decrease in DPD and OCN (Fig. 1A). In femur
and lumbar vertebrae, BMDwas decreased by OVX and it was inhibited
by IBN. High dose of IBN even showed signiﬁcant increase of BMD com-
paredwith sham (at 30 μg/kg in lumbar and at over 10 μg/kg in femoral
BMD) a decrease in BMD was not only inhibited but also increased
(Fig. 1B). So that 3 μg/kg IBN treatment resulted in a BMD in the lumbar
vertebrae and femur comparable to that of the Sham group.
3.2. A combined therapy experiment
3.2.1. Body weight, serum calcium or phosphorous after
combination treatment
After the dose-ﬁnding study, we investigated the effects of combina-
tion treatmentwith IBNplus ELDunder conditions of estrogendeﬁciency
using OVX rats. The dose of 3 μg/kg for IBN was used in this experiment
because it increased lumbar and femoral BMD inOVX rats to a level com-
parable to that of the Sham group (Fig. 1B). Rats were allocated into 5
groups (Table 1) as follows: vehicle-treated sham-operated rats (admin-
istered saline and ELD vehicle);, vehicle-treated OVX rats (administered
saline and ELD vehicle);, OVX rats treated with IBN (administered IBN
and ELD vehicle);, OVX rats treated with ELD (administered saline and
ELD); and, combination treatment with IBN plus ELD. IBN or saline was
subcutaneously administered once every 4 weeks, and ELD or MCT was
orally administered every day.
Body weight and concentrations of calcium and phosphorus in
serum are shown in Table 2. The bodyweight of OVX rats in the Vehiclegroup was signiﬁcantly higher than rats in the Sham group throughout
the course of the experiment. Treatmentwith IBN, ELD, or the combina-
tion had no effect on body weight. ELD increased serum calcium and
phosphorus as previously reported [13], and serum phosphorus in the
Combination group at Week 4 showed no signiﬁcant change as com-
pared to that in the Sham group. Serum calcium and phosphorus were
increased in the ELD group at all sampling times. In the Combination
group, no differences were seen in any of these parameters other than
the concentration of phosphorus at Week 4.
3.2.2. Bone turnover markers, lumber and femur BMD and
mechanical properties
The bone resorption marker DPD in urine was increased in the
Vehicle group throughout the experimental period (Fig. 2A). Monother-
apieswith IBN or ELD signiﬁcantly inhibited theOVX-related rise inDPD
within 4weeks, and the valueswere decreased below those of the Sham
Table 2
Body weight and serum concentrations of calcium and phosphorous.
Sham Vehicle IBN ELD Combination
Body weight (g)
Week 4 314 ± 11 367 ± 28⁎ 359 ± 20 376 ± 14 374 ± 18
Week 8 325 ± 13 380 ± 27⁎ 373 ± 22 395 ± 16 395 ± 21
Week 12 339 ± 15 400 ± 30⁎ 393 ± 17 416 ± 17 413 ± 19
Serum calcium (mg/dL)
Week 4 9.77 ± 0.19 9.90 ± 0.26 10.12 ± 0.22 10.68 ± 0.34§,I 10.83 ± 0.25§,I
Week 8 9.85 ± 0.25 9.77 ± 0.29 9.69 ± 0.19 10.79 ± 0.29§,I 10.77 ± 0.30§,I
Week 12 9.89 ± 0.28 9.64 ± 0.30 9.60 ± 0.12 10.59 ± 0.29§,I 10.38 ± 0.22§,I
Serum phosphorus (mg/dL)
Week 4 3.99 ± 0.43 4.79 ± 0.68⁎ 5.22 ± 0.48 5.71 ± 0.63§ 5.36 ± 0.37
Week 8 4.05 ± 0.48 4.40 ± 0.65 4.20 ± 0.31 5.61 ± 0.58§,I 5.72 ± 0.59§,I
Week 12 3.97 ± 1.11 3.98 ± 0.79 4.24 ± 0.94 5.79 ± 1.10§,I 5.51 ± 0.55§,I
Data are presented as mean ± S.D. (n = 10).
IBN, ibandronate; ELD, eldecalcitol.
⁎ p b 0.05 Sham group vs. Vehicle group by unpaired t-test.
§ p b 0.05 vs. Vehicle.
I p b 0.05 vs. IBN by Tukey's multiple comparison test.
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ergistic effect throughout the experiment. On the other hand, although
the bone formation marker, serum OCN, was increased in the Vehicle
group, it was not remarkably changed following administration of IBN
or ELD alone or even in combination (Fig. 2B).
At the end of the 12 week treatment, BMD of the lumbar spine was
signiﬁcantly decreased in the Vehicle group as compared to that in the
Sham group (Fig. 3A). A synergistic increase was observed in the
Combination group. The same result was observed with femoral BMD,
both in the proximal and distal femur, which consist of abundant tra-
becular bone, and in the middle femur, which consists of cortical bone
(Fig. 3B, C).
To assess bone mechanical properties, compression tests of the L5
lumbar vertebra and a 3-point bending test of the middle femur were
performed. In the Vehicle group, the ultimate load of the lumbar verte-
bra and femur were signiﬁcantly diminished (Fig. 4A and B). Treatment
of OVX rats with either IBN or ELD alone prevented the decrease in lum-
bar ultimate load. Combination treatment did not interfere with the
effects of these drugs on the ultimate load of the lumbar vertebra
(Fig. 4A). With respect to the ultimate load of cortical bone, monother-
apy groups showed a slight tendency for bone ultimate load to increase,
and when compared to Vehicle group, combination treatment had
signiﬁcantly increased femoral ultimate load as assessed by 3-point
bending test (Fig. 4B).3.2.3. Bone histomorphometry analysis
To examine the way of increasing BMD and bone ultimate load
seen in combination therapy with IBN plus ELD, we focused on the
uncoupling of bone formation from bone resorption shown in Fig. 2.
To investigate more precisely the state of bone turnover in the Combi-
nation group, histomorphometric analysis of trabecular bone was per-
formed in the third lumbar vertebra (L3). Typical photos of bright ﬁeld
and ﬂuorescence image were demonstrated in Fig. 5. Fluorescence
imaging can visualize bone mineralizing surface as bright lines. Bone
volume was decreased in Vehicle group compared with Sham group
(white area in bright ﬁeld image or black area in ﬂuorescence image).
The reduction was prevented by IBN or ELD, and the combination of
IBN plus ELD had a synergistic effect on trabecular thickness (width of
bone area) (Fig. 5).
The quantitative analysis of bone histomorphometry was per-
formed. In all experimental groups, including the Combination group,
bone mineralization was maintained on the surface of trabecular bone.
Bone resorption parameters (Oc.S/BS, ES/BS, N.Oc/BS) were increasedin the Vehicle group, and monotherapy with IBN or ELD decreased
these parameters (Table 3).
The combination treatment showed greater inhibition of bone re-
sorption than did IBN alone. Bone formation parameters (Ob.S/BS,
N.Ob/BS, OS/BS, MS/BS, BFR/BS, MAR, Ac.f) were also increased in the
Vehicle group and were reduced in the IBN group and the ELD group.
While combination treatment facilitated the reduction of bone resorp-
tion, no signiﬁcant changes in bone formation parameters were
observed in the Combination group as compared to the IBN group or
the ELD group; this result was identical to that found with serum and
urine bone turnover markers (Fig. 2). Interestingly, “bud” shaped bone
formation was also observed in ELD-treated rats (the ELD group and
the IBN plus ELD combination group) (Fig. 6A). The formation of bud-
shaped bone on the smooth cement lines of intact lamellar bone
is called “minimodeling” [9] and is independent of bone resorption
[16]. In the Vehicle group, different from the increased remodeling
and high bone turnover, there was no increase in the number of
minimodeling sites, length of minimodeling surfaces, or bone volume
of minimodeling (Fig. 6B). Minimodeling parameters were not affected
by the inhibition of bone resorption in the IBN group. Although the same
level of reduction in bone resorption was observed in the ELD group as
in the IBN group (Table 3), minimodeling in the ELD groupwas remark-
ably upregulated as previously reported [10]. Furthermore, the combi-
nation treatment with IBN plus ELD did not interfere with the bone
formation by minimodeling as compared to the ELD-treated group
(Fig. 6B).
4. Discussion
In the present study we demonstrated that combination treatment
with IBN plus ELD—a nitrogen-containing bisphosphonate plus an
active vitamin D3 derivative—had an advantageous effect on BMD and
bone ultimate load in both the lumbar vertebrae and femur in OVX
aged rats. Since the rats were 8 months of age at start of the study,
growth-dependent effects, which may have inﬂuenced the results, can
be neglected. We chose the dose of 3 μg/kg for the combination experi-
ment because that dose was the maximal dose which didn't show the
signiﬁcant increase BMD compared to sham operated rats. We chose
15 ng/kg of ELD in the combination treatment on the basis of our previ-
ous results [13]. ELD is administered at 0.75 μg/kg per day in clinical
treatment, so 15 ng/kg is almost the same dose as in clinical use.
Interestingly, at the doses used in this study, IBN showed almost the
same efﬁcacy as ELDwith respect to femoral ultimate load. It is reported
that IBN exerts its anti-osteoporotic effect, and a greater beneﬁcial result
Fig. 2. Combination treatmentwith IBN plus ELD had inhibitory effects on bone resorption,with the level of bone formation being comparable to that of the Shamgroup. (A)Monotherapy
with IBN or ELD signiﬁcantly decreased urinary DPD, and the combination of IBN plus ELD showed grater inhibition throughout the experiment. (B) Serum OCN was increased in the
Vehicle group. Treatment with IBN, ELD, or the combination of IBN plus ELD did not markedly suppress the increased OCN. n= 10. *, p b 0.05 vs. Sham by t-test; —, p b 0.05 by Tukey's
multiple comparison test. IBN, ibandronate; ELD, eldecalcitol; DPD, deoxypiridinorine; Cr, creatinine; OCN, osteocalcin.
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our detailed investigation of combination treatment with IBN plus
ELD, IBN and ELD acted synergistically to reduce bone resorption
in OVX rats, in which both bone resorption and bone formation isaccelerated. These two drugs have different mechanisms of action in
the inhibition of bone resorption, andwe consider that this is the reason
behind this enhanced effect of combination treatment on bone resorp-
tion. Although higher doses of each monotherapy, in particular with
Fig. 3. Combination treatment with IBN plus ELD had a synergistic effect on both trabecular and cortical BMD. Lumbar vertebrae (L2–L4) and femurs were collected after 12 weeks treat-
ment. Both lumbar and femoral BMDwere reduced in the Vehicle group, andmonotherapywith either IBN or ELD reversed this reduction. Combination treatment resulted in an additive
increase in both trabecular BMD (lumbar, proximal anddistal femur) and cortical BMD (middle femur) compared tomonotherapywith IBN or ELD. n=10. *, p b 0.05 vs. Shamby t-test;—,
p b 0.05 by Tukey's multiple comparison test. IBN, ibandronate; ELD, eldecalcitol; BMD, bone mineral density.
454 S. Sakai et al. / Bone 81 (2015) 449–458IBN, had demonstrated higher increases in BMD than the combination
therapy, the combination therapy has the advantage to combine both
modes of action at lower doses, with the beneﬁt of vitamin-related
increased calcium absorption from the intestine.
It has been reported that bisphosphonates bind to the bone sur-
face and are released under low pH conditions during bone resorp-
tion whereupon they are incorporated into osteoclasts and, at high
concentrations, induce apoptosis [18]; it is also reported that they
stimulate the expression of bone resorption inhibitors from osteo-
blasts in vitro [19]. Farnesyl diphosphate synthase is the target of
nitrogen-containing bisphosphonates in osteoclasts, and it is report-
ed that the effect of IBN on the inhibition of this enzyme is greater
than that of alendronate [2]. Since IBN has a more convenient dosing
regimen than e.g. alendronate, with a higher compliance, adhesion
and persistence to therapy, IBN is the more preferred combination
partner for ELD than other bisphosphonates [20]. ELD, on the other
hand, inhibits osteoclast differentiation directly through inhibition
of NFATc1 ampliﬁcation, which is the critical transcription factor in os-
teoclastogenesis. ELD upregulates the mRNA expression of IFN-β [21]
and inhibits the c-Fos translation which is the transcription factor ofNFATc1 in osteoclast progenitor cells [22]. In addition to direct inhibi-
tion of osteoclastogenesis, ELD controls the migration of osteoclast
precursors through regulation of sphingosine-1-phosphate signaling
in osteoclast precursor cells [23]. ELD also reduces the expression of
RANKL (receptor activator of NF-κB ligand) in bone tissue, a stimula-
tor of osteoclast differentiation and bone resorption [24]. In this way,
IBN attaches to the bone surface and is released to exert its anti-bone
resorptive capacity at the bone resorption stage, whereas ELD acts at
the osteoclast differentiation stage. This temporal difference in
the mode of action on osteoclastogenesis may be the reason why
these two drugs exert a synergistic effect on the reduction of bone
resorption.
Despite of its synergistic effect on bone resorption, the combination
treatment did not show greater inhibition of bone formation than did
either monotherapy. In general, in animals or humans with accelerated
bone turnover, inhibition of bone resorption causes downregulation of
bone formation because bone formation is induced by bone resorption
in the remodeling cycle. Stronger inhibition of bone resorption parallels
the effect on BMD in osteoporosis patients, so the balance between
reducing bone resorption and maintaining bone turnover is the key
Fig. 4. Combination treatment with IBN plus ELD increased lumbar and femoral bone strength. (A) Monotherapywith IBN or ELD increased lumbar ultimate load. Combination treatment
did not interferewith the effect ofmonotherapy and enhanced bone strength as compared to the Vehicle group. (B)Monotherapywith IBN or ELD showed a tendency to increase femoral
bone strength, and combination treatment signiﬁcantly increased femoral midshaft strength. n= 10. *, p b 0.05 vs. Sham by t-test; —, p b 0.05 by Tukey's multiple comparison test. IBN,
ibandronate; ELD, eldecalcitol.
455S. Sakai et al. / Bone 81 (2015) 449–458issue of effective treatment of osteoporosis. It is reported that ELD ad-
ministered simultaneously with alendronate showed a synergistic effect
on the reduction of bone resorption and a dose-dependent increase in
bone formation [13]. In the present study, we focused on minimodeling
as a cause of this uncoupling of bone formation/bone resorption observedin the combination treatment with bisphosphonate plus active vitamin
D3 derivative, because it is reported that calcitriol and ELD both stimulat-
ed minimodeling based bone formation in distal femur of OVX rats even
though the efﬁcacy of ELD on minimodeling was much greater than
calcitriol [25].
Fig. 5.Mineralizing surfaces were seen in all groups. Representative images of trabecular bone (L3) from all experimental groups are shown. Scale bar, 100 μm.
456 S. Sakai et al. / Bone 81 (2015) 449–458Minimodeling is a process of bone formation on quiescent bone sur-
faces without bone resorption that continues throughout life [16].
Minimodeling observed in human iliac bone is reported to account for
less than 1% of the trabecular bone volume and about 2% of the entire
bone surface [9]. In this study, minimodeling in sham operated rats
was calculated to account for 0.14% of bone volume and 2.13% of bone
surface in the lumbar vertebrae. Thus, there is no discrepancy between
the previous report of minimodeling in human iliac bone and ourpresent data on minimodeling in lumbar cancellous bone of rats [9]. In
the Vehicle group, although the markers of bone resorption and forma-
tion in urine and serum and the parameters of bone resorption and for-
mation in bone histomorphometry were increased, minimodeling was
not shown to be signiﬁcantly different from that in the Sham group.
This fact indicated that minimodeling is not affected by accelerated
bone turnover and so is different from remodeling in this respect. In the
ELD group, the number of minimodeling sites, length of minimodeling
Table 3
Bone morphometry parameters (trabecular bone).
Sham Vehicle IBN ELD Combination
BV/TV (%) 29.5 ± 4.4 22.7 ± 3.1⁎ 32.0 ± 4.8§ 35.8 ± 6.8§ 38.6 ± 4.7§,I
Tb.Th (μm) 84.0 ± 5.6 71.7 ± 8.6⁎ 87.6 ± 15.4 97.3 ± 17.1§ 103.7 ± 14.4§
Tb.Sp (μm) 205.4 ± 37.8 245.0 ± 22.8⁎ 186.9 ± 23.4§ 178.3 ± 39.5§ 165.0 ± 18.6§
Tb.N (/mm) 3.51 ± 0.45 3.17 ± 0.20⁎ 3.67 ± 0.35§ 3.69 ± 0.49§ 3.74 ± 0.28§
Oc.S/BS (%) 4.86 ± 1.32 7.52 ± 2.14⁎ 2.52 ± 1.14§ 1.22 ± 0.84§ 0.43 ± 0.21§,I
ES/BS (%) 19.7 ± 4.0 28.2 ± 6.1⁎ 9.2 ± 3.9§ 4.0 ± 3.4§,I 1.2 ± 0.7§,I
N.Oc/BS (/mm) 1.65 ± 0.39 2.57 ± 0.74⁎ 0.84 ± 0.35§ 0.49 ± 0.26§ 0.24 ± 0.11§,I
Ob.S/BS (%) 3.17 ± 1.82 14.39 ± 3.31⁎ 5.15 ± 2.23§ 6.29 ± 1.84§ 6.19 ± 3.11§
N.Ob/BS (/mm) 2.87 ± 1.43 11.21 ± 2.28⁎ 4.79 ± 1.75§ 6.58 ± 2.26§ 6.24 ± 2.98§
MS/BS (%) 5.55 ± 3.46 23.48 ± 5.35⁎ 6.94 ± 3.27§ 7.89 ± 1.68§ 5.58 ± 2.47§
OS/BS (%) 4.89 ± 2.76 21.27 ± 4.75⁎ 8.22 ± 3.36§ 10.62 ± 3.20§ 10.48 ± 5.42§
BFR/BS (mm3/mm2/year) 0.029 ± 0.020 0.163 ± 0.038⁎ 0.038 ± 0.020§ 0.044 ± 0.013§ 0.030 ± 0.015§
MAR (μm/day) 1.38 ± 0.21 1.90 ± 0.10⁎ 1.48 ± 0.24§ 1.50 ± 0.22§ 1.41 ± 0.22§
Ac.f (/year) 1.20 ± 0.71 9.08 ± 2.07⁎ 1.91 ± 0.94§ 2.04 ± 0.64§ 1.36 ± 0.69§
Data are presented as mean ± S.D. (n = 10).
IBN, ibandronate; ELD, eldecalcitol.
⁎ p b 0.05 vs. Sham group by unpaired t-test.
§ p b 0.05 vs. Vehicle.
I p b 0.05 vs. IBN by Tukey's multiple comparison test.
457S. Sakai et al. / Bone 81 (2015) 449–458surfaces, or bone volume of minimodeling were increased as has been
previously reported [10], and combination treatment did not interfere
with this upregulation.
In conclusion, we demonstrated the beneﬁt of combination treat-
mentwith IBN plus ELD. The combination treatment showed synergisticFig. 6. (A) Representative images of minimodeling in cancellous bone (IBN plus ELD combina
polarized, and ﬂuorescence images are shown. (B) Minimodeling-based bone formation wa
level of minimodeling was not changed from that in the Sham group despite increased bone fo
metric analysis. Bone formation byminimodelingwas signiﬁcantly increased in the ELDgroup a
comparison test. IBN, ibandronate; ELD, eldecalcitol; N.Ml./BS, minimodeling number; Ml.BS, minhibition of bone resorption, with bone formation at the same level as
in the Sham group. Minimodeling—bone formation independent of
bone resorption—may play a part in the uncoupling of bone resorp-
tion/bone formation seen with the combination treatment. This combi-
nation regimen of IBN plus ELD will help in the efﬁcient long-termtion treatment). Minimodeling formed budding on quiescent bone surfaces. Bright-ﬁeld,
s stimulated in the combination treatment with IBN plus ELD. In the Vehicle group, the
rmation markers in serum and increased bone formation parameters in the bonemorpho-
nd Combination group. n=10. *, p b 0.05 vs. Shamby t-test;—, p b 0.05 by Tukey'smultiple
inimodeling surface; Ml.BV/TV, minimodeling volume.
458 S. Sakai et al. / Bone 81 (2015) 449–458treatment of osteoporosis without inducing severe suppression of bone
turnover in osteoporosis patients.
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